A Randomized, Double‐Blind, Parallel‐Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects

A comparison of the immunogenicity, safety, and pharmacokinetic properties of HS016 and its originator, adalimumab, was conducted in Chinese healthy male subjects. This was a phase 1 single‐center, randomized, parallel‐group double‐blind clinical trial. Chinese healthy male subjects (1:1) allocated...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Guoying, Yu, Jicheng, Wu, Jufang, Wang, Jingjing, Xue, Yu, Yang, Xiaoli, Zhang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984335/
https://www.ncbi.nlm.nih.gov/pubmed/32463599
http://dx.doi.org/10.1002/cpdd.816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984335/
https://www.ncbi.nlm.nih.gov/pubmed/32463599
http://dx.doi.org/10.1002/cpdd.816

Ejemplares similares